PMID- 12149200
OWN - NLM
STAT- MEDLINE
DCOM- 20020912
LR  - 20220309
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 100
IP  - 4
DP  - 2002 Aug 15
TI  - The clinical significance of tumor necrosis factor-alpha plasma level in patients 
      having chronic lymphocytic leukemia.
PG  - 1215-9
AB  - Tumor necrosis factor-alpha (TNF-alpha), a cytokine possessing pleiotropic 
      biological activities, is produced by leukemic lymphocytes in patients with 
      chronic lymphocytic leukemia (CLL) and acts as an autocrine and paracrine growth 
      factor in this disease. In this study, TNF-alpha levels were determined in 150 
      patients with CLL and correlated with disease characteristics, prognostic 
      factors, and survival. The mean TNF-alpha plasma concentration in the patients 
      with CLL was significantly higher than in the healthy control population (16.4 
      versus 8.7 pg/mL; P <.0001). Patients having an elevated TNF-alpha level had more 
      advanced Rai and Binet stage disease, higher serum beta(2)-microglobulin 
      (beta(2)M) levels, a greater percentage of cells expressing CD38, and lower 
      hemoglobin and platelet levels. Patients having chromosomal abnormalities such as 
      11q deletion, trisomy 12, and chromosome 17 aberrations had a higher mean 
      TNF-alpha level (27.5 pg/mL) than patients having a diploid karyotype or other 
      miscellaneous cytogenetic abnormalities (14.2 pg/mL; P <.001). The TNF-alpha 
      level was a predictor of survival when the Cox proportional hazards model was 
      used with TNF-alpha entered as a continuous variable (P =.0001). Also, patients 
      having a TNF-alpha level above the mean value of 14 pg/mL had significantly 
      shorter survival duration (P =.00001). The TNF-alpha level remained predictive of 
      survival in Cox multivariate analysis independent of Rai staging and beta(2)M, 
      hemoglobin, prior therapy, white cell count, and platelet level (P =.005). We 
      conclude that the TNF-alpha level serves as a prognostic factor in patients with 
      CLL and that inhibition of TNF-alpha in these patients could have therapeutic 
      importance.
FAU - Ferrajoli, Alessandra
AU  - Ferrajoli A
AD  - Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, 
      Houston 77030, USA.
FAU - Keating, Michael J
AU  - Keating MJ
FAU - Manshouri, Taghi
AU  - Manshouri T
FAU - Giles, Francis J
AU  - Giles FJ
FAU - Dey, Amanda
AU  - Dey A
FAU - Estrov, Zeev
AU  - Estrov Z
FAU - Koller, Charles A
AU  - Koller CA
FAU - Kurzrock, Razelle
AU  - Kurzrock R
FAU - Thomas, Deborah A
AU  - Thomas DA
FAU - Faderl, Stefan
AU  - Faderl S
FAU - Lerner, Susan
AU  - Lerner S
FAU - O'Brien, Susan
AU  - O'Brien S
FAU - Albitar, Maher
AU  - Albitar M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation)
RN  - 0 (Hemoglobins)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (beta 2-Microglobulin)
RN  - EC 3.2.2.5 (ADP-ribosyl Cyclase)
RN  - EC 3.2.2.5 (CD38 protein, human)
RN  - EC 3.2.2.5 (NAD+ Nucleosidase)
RN  - EC 3.2.2.6 (ADP-ribosyl Cyclase 1)
SB  - IM
MH  - ADP-ribosyl Cyclase
MH  - ADP-ribosyl Cyclase 1
MH  - *Antigens, CD
MH  - Antigens, Differentiation/analysis
MH  - Chromosome Aberrations
MH  - Chromosomes, Human, Pair 11
MH  - Chromosomes, Human, Pair 12
MH  - Chromosomes, Human, Pair 17
MH  - Gene Deletion
MH  - Hemoglobins/analysis
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*blood/mortality
MH  - Membrane Glycoproteins
MH  - NAD+ Nucleosidase/analysis
MH  - Neoplasm Staging
MH  - Platelet Count
MH  - Prognosis
MH  - Survival Rate
MH  - Trisomy
MH  - Tumor Necrosis Factor-alpha/*analysis
MH  - beta 2-Microglobulin/blood
EDAT- 2002/08/01 10:00
MHDA- 2002/09/13 10:01
CRDT- 2002/08/01 10:00
PHST- 2002/08/01 10:00 [pubmed]
PHST- 2002/09/13 10:01 [medline]
PHST- 2002/08/01 10:00 [entrez]
AID - S0006-4971(20)59311-7 [pii]
PST - ppublish
SO  - Blood. 2002 Aug 15;100(4):1215-9.